XU Hai-peng, LIN Gen, HUANG Jie. Pembrolizumab plus Etoposide and Platinum as First-Line Therapy for Small-Cell Lung Cancer: KEYNOTE-604 Study[J]. Journal of Evidence-Based Medicine, 2020, 20(3): 155-157. DOI: 10.12019/j.issn.1671-5144.2020.03.006
|
Citation:
|
XU Hai-peng, LIN Gen, HUANG Jie. Pembrolizumab plus Etoposide and Platinum as First-Line Therapy for Small-Cell Lung Cancer: KEYNOTE-604 Study[J]. Journal of Evidence-Based Medicine, 2020, 20(3): 155-157. DOI: 10.12019/j.issn.1671-5144.2020.03.006
|
XU Hai-peng, LIN Gen, HUANG Jie. Pembrolizumab plus Etoposide and Platinum as First-Line Therapy for Small-Cell Lung Cancer: KEYNOTE-604 Study[J]. Journal of Evidence-Based Medicine, 2020, 20(3): 155-157. DOI: 10.12019/j.issn.1671-5144.2020.03.006
|
Citation:
|
XU Hai-peng, LIN Gen, HUANG Jie. Pembrolizumab plus Etoposide and Platinum as First-Line Therapy for Small-Cell Lung Cancer: KEYNOTE-604 Study[J]. Journal of Evidence-Based Medicine, 2020, 20(3): 155-157. DOI: 10.12019/j.issn.1671-5144.2020.03.006
|
DownLoad: